After months of pursuit, Takeda Pharmaceuticals (TKPYY) finally won over Shire (SHPG) with a $62 billion offer, a move that will create the world’s eighth-largest drug maker with combined sales worth $30 billion. And for Takeda chief executive Christophe Weber, the deal will cap his quest to expand the Japanese drug maker into more profitable markets, notably the U.S.

Once completed — the target date is the first half of 2019 — the combined company will become a leader in therapies for a variety of maladies. But Takeda is borrowing cash to pay for the deal, worrying shareholders about its debt load, especially after borrowing money to buy Ariad Pharmaceuticals last year for $5 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What a waste of money! There will be no respectable return on investment in five even in ten years.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy